In:
Head & Neck, Wiley, Vol. 38, No. 4 ( 2016-04), p. 529-535
Kurzfassung:
Patients with human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (SCC) have a better survival than with HPV‐negative oropharyngeal SCC. An 18 F‐fluorodeoxyglucose positron emission tomography‐CT ( 18 F‐FDG‐PET‐CT) may also provide prognostic information. We evaluated glycolytic characteristics in HPV‐negative and HPV‐positive oropharyngeal SCC. Methods Forty‐four patients underwent pretreatment 18 F‐FDG‐PET‐CT. Standardized uptake values (SUVs) and metabolic active tumor volumes (MATVs) were determined for primary tumors. HPV status was determined with p16 immunostaining, followed by high‐risk HPV DNA detection on the positive cases. Results Twenty‐seven patients were HPV‐positive (61.4%). Median MATV was 2.8 mL (range = 1.6–5.1 mL) for HPV‐positive and 6.0 mL (range = 4.4–18.7 mL) for HPV‐negative tumors ( p 〈 .001). SUV values are volume dependent (partial volume effect), therefore, MATV was included as covariate in multivariate analysis. In this multivariate analysis, the maximum SUV in HPV‐positive tumors was 3.9 units lower than in HPV‐negative tumors ( p = .01). Conclusion The 18 F‐FDG‐PET‐CT parameters are lower in HPV‐positive than in HPV‐negative patients. Low pretreatment SUV values in HPV‐positive oropharyngeal SCC may be at least partly explained by HPV‐induced tumor changes. © 2015 Wiley Periodicals, Inc. Head Neck 38: 529–535, 2016
Materialart:
Online-Ressource
ISSN:
1043-3074
,
1097-0347
Sprache:
Englisch
Verlag:
Wiley
Publikationsdatum:
2016
ZDB Id:
2001440-5
